Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference
Werewolf Therapeutics (NASDAQ: HOWL), a biopharmaceutical company focused on developing conditionally activated therapeutics for cancer immunotherapy, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's President and CEO Daniel J. Hicklin, Ph.D., along with Chief Medical Officer Randi Isaacs, M.D., will engage in a fireside chat on June 5, 2025, at 4:20 PM EDT.
The conference is scheduled for June 3-5, 2025. Interested parties can access a live webcast of the presentation through the company's investor relations website, with a replay available for approximately 90 days after the event.
Werewolf Therapeutics (NASDAQ: HOWL), un'azienda biofarmaceutica specializzata nello sviluppo di terapie condizionalmente attivate per l'immunoterapia oncologica, ha annunciato la sua partecipazione alla prossima Jefferies Global Healthcare Conference. Il Presidente e CEO Daniel J. Hicklin, Ph.D., insieme al Chief Medical Officer Randi Isaacs, M.D., parteciperanno a una conversazione informale il 5 giugno 2025 alle 16:20 EDT.
La conferenza si terrà dal 3 al 5 giugno 2025. Gli interessati potranno seguire la presentazione in diretta streaming tramite il sito web delle relazioni con gli investitori dell'azienda, con la possibilità di rivederla in replica per circa 90 giorni dopo l'evento.
Werewolf Therapeutics (NASDAQ: HOWL), una compañía biofarmacéutica enfocada en el desarrollo de terapias condicionalmente activadas para la inmunoterapia contra el cáncer, ha anunciado su participación en la próxima Jefferies Global Healthcare Conference. El presidente y CEO Daniel J. Hicklin, Ph.D., junto con la directora médica Randi Isaacs, M.D., participarán en una charla informal el 5 de junio de 2025 a las 4:20 PM EDT.
La conferencia está programada del 3 al 5 de junio de 2025. Los interesados podrán acceder a una transmisión en vivo de la presentación a través del sitio web de relaciones con inversores de la compañía, con una repetición disponible aproximadamente por 90 días después del evento.
Werewolf Therapeutics (NASDAQ: HOWL)는 암 면역 치료를 위한 조건부 활성화 치료제 개발에 주력하는 바이오제약 회사로, 다가오는 Jefferies Global Healthcare Conference에 참여한다고 발표했습니다. 회사의 사장 겸 CEO인 Daniel J. Hicklin 박사와 최고 의료 책임자 Randi Isaacs 박사가 2025년 6월 5일 오후 4시 20분 EDT에 화기애애한 대화를 진행할 예정입니다.
컨퍼런스는 2025년 6월 3일부터 5일까지 개최됩니다. 관심 있는 분들은 회사 투자자 관계 웹사이트를 통해 발표를 생중계로 시청할 수 있으며, 행사 후 약 90일간 재방송도 제공됩니다.
Werewolf Therapeutics (NASDAQ: HOWL), une société biopharmaceutique spécialisée dans le développement de thérapies conditionnellement activées pour l'immunothérapie du cancer, a annoncé sa participation à la prochaine Jefferies Global Healthcare Conference. Le président et CEO Daniel J. Hicklin, Ph.D., ainsi que la directrice médicale Randi Isaacs, M.D., participeront à une discussion informelle le 5 juin 2025 à 16h20 EDT.
La conférence se tiendra du 3 au 5 juin 2025. Les personnes intéressées pourront suivre la présentation en direct via le site web des relations investisseurs de la société, avec une rediffusion disponible pendant environ 90 jours après l'événement.
Werewolf Therapeutics (NASDAQ: HOWL), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung bedingt aktivierter Therapeutika für die Krebsimmuntherapie spezialisiert hat, hat seine Teilnahme an der kommenden Jefferies Global Healthcare Conference angekündigt. Der Präsident und CEO Daniel J. Hicklin, Ph.D., zusammen mit der Chief Medical Officer Randi Isaacs, M.D., werden am 5. Juni 2025 um 16:20 Uhr EDT an einem informellen Gespräch teilnehmen.
Die Konferenz findet vom 3. bis 5. Juni 2025 statt. Interessierte können die Präsentation live über die Investor-Relations-Website des Unternehmens verfolgen, mit einer Wiedergabe, die etwa 90 Tage nach der Veranstaltung verfügbar sein wird.
- None.
- None.
WATERTOWN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer and Randi Isaacs, M.D., Chief Medical Officer, both of Werewolf Therapeutics, will participate in a fireside chat at 4:20 PM EDT on Thursday, June 5, 2025, at the Jefferies Global Healthcare Conference, taking place on June 3-5, 2025.
A live webcast link for the presentation will be available at https://investors.werewolftx.com/news-and-events/events. An archived replay will be available for approximately 90 days following the event.
About Werewolf Therapeutics:
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The Company is leveraging its proprietary PREDATOR® platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent. To learn more visit www.werewolftx.com.
WEREWOLF®, the WEREWOLF logo, PREDATOR®, INDUKINE™ and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved.
Investor Contact Dan Ferry LifeSci Advisors 617.430.7576 daniel@lifesciadvisors.com Media Contact: Amanda Sellers Deerfield Group 301.332.5574 amanda.sellers@deerfieldgroup.com Company Contact: Timothy Trost Chief Financial Officer Werewolf Therapeutics ttrost@werewolftx.com
FAQ
When is Werewolf Therapeutics (HOWL) presenting at the Jefferies Healthcare Conference 2025?
Who will represent Werewolf Therapeutics (HOWL) at the Jefferies Conference?
How can I watch Werewolf Therapeutics' (HOWL) presentation at the Jefferies Conference?
What is Werewolf Therapeutics' (HOWL) main focus as a company?
